SCHEMBL17429451

SCHEMBL17429451

Cc1cc2[nH]c(C(=O)O)cc2cc1F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4A3 P38919 4/20 0.65
GPR35 Q9HC97 1/20 0.56
KDM4E B2RXH2 2/20 0.56
HPGD P15428 2/20 0.56
HSD17B10 Q99714 2/20 0.56
PIN1 Q13526 1/20 0.56
PDPK1 O15530 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
APEX1 P27695 1/20 0.56
CYP2C19 P33261 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
SMAD3 P84022 1/20 0.49
F7 P08709 1/20 0.47
F3 P13726 1/20 0.47
DAO P14920 2/20 0.47
SRD5A2 P31213 2/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL765246 0.93 EIF4A3 (0.60) EIF4A3GPR35KDM4EHPGDHSD17B10
SCHEMBL7682186 0.85 GPR35 (0.63) EIF4A3GPR35KDM4EHPGDHSD17B10
SCHEMBL1822934 0.85 EIF4A3 (0.68) EIF4A3GPR35KDM4EHPGDHSD17B10
SCHEMBL14205189 0.82 XDH (0.48) EIF4A3KDM4EHPGDHSD17B10ALDH1A1
SCHEMBL4041495 0.80 KDM4E (0.63) EIF4A3KDM4EHPGDHSD17B10ALDH1A1
SCHEMBL3639230 0.79 EIF4A3 (0.60) EIF4A3GPR35KDM4EHPGDHSD17B10
SCHEMBL22747199 0.79 GPR35 (0.56) EIF4A3GPR35KDM4EHPGDHSD17B10
SCHEMBL1144612 0.79 EIF4A3 (0.60) EIF4A3GPR35KDM4EHPGDHSD17B10
SCHEMBL25812185 0.79 ALOX15 (0.57) EIF4A3KDM4EALDH1A1MAPTKMT2A
SCHEMBL29301295 0.78 EIF4A3 (0.77) EIF4A3GPR35KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-20170166561-A1 QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY ALPHARMAGEN LLC (US) 2017-06-15 US disclosed
US-9434724-B2 Quinuclidines for modulating alpha 7 activity ALPHARMAGEN, LLC (US) 2016-09-06 US disclosed
US-20160009706-A1 QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY ALPHARMAGEN, LLC 2016-01-14 US disclosed
CN-1277828-C Piperzine devivs. HOFFMANN LA ROCHE (CH) 2006-10-04 CN disclosed
CN-1245405-C Piperazine derivatives HOFFMANN LA ROCHE (CH) 2006-03-15 CN disclosed
CN-1529706-A Piperazine derivatives - 2004-09-15 CN disclosed
CN-1452622-A Piperzine devivs. HOFFMANN LA ROCHE (CH) 2003-10-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 EIF4A3 1474/4885GPR35 1909/4885KDM4E 1496/4885
US-20160009706-A1 QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY CHRNA7, CHRNA2, CHRNA5 EIF4A3 4663/4885GPR35 269/4885KDM4E 3461/4885
US-20170166561-A1 QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY CHRNA7, CHRNA2, CHRNA6 EIF4A3 4810/4885GPR35 206/4885KDM4E 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.